Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL824415 | 1.00 | HSD17B10 (0.48) | HSD17B10TDP1HTTHCAR3NPC1 | |
| SCHEMBL824437 | 0.93 | TDP1 (0.49) | HSD17B10TDP1HTTHCAR3NPC1 | |
| SCHEMBL824442 | 0.93 | HSD17B10 (0.53) | HSD17B10TDP1HTTHCAR3NPC1 | |
| SCHEMBL16488365 | 0.82 | PDE2A (0.40) | HSD17B10TDP1HCAR3NPC1RAB9A | |
| SCHEMBL18818916 | 0.78 | FGFR1 (0.48) | HSD17B10HTTHCAR3NPC1RAB9A | |
| SCHEMBL7606903 | 0.76 | KMT2A (0.53) | HSD17B10TDP1HTTHCAR3NPC1 | |
| SCHEMBL7604980 | 0.76 | KMT2A (0.53) | HSD17B10TDP1HTTHCAR3NPC1 | |
| SCHEMBL4549641 | 0.75 | HSD17B10 (0.43) | HSD17B10TDP1HTTHCAR3NPC1 | |
| SCHEMBL4549640 | 0.75 | TDP1 (0.42) | HSD17B10TDP1HTTHCAR3NPC1 | |
| SCHEMBL4549638 | 0.74 | HSD17B10 (0.40) | HSD17B10TDP1HTTHCAR3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2291703-B1 | COLOR LIQUID CRYSTAL DISPLAY AND COMPENSATION PANEL | CRYSOPTIX KK (JP) | 2016-11-30 | — | — | EP | disclosed |
| EP-2638126-B1 | NEGATIVE DISPERSION RETARDATION PLATE AND ACHROMATIC CIRCULAR POLARIZER | CRYSOPTIX KK (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-8895118-B2 | Negative dispersion retardation plate and achromatic circular polarizer | CRYSOPTIX K.K. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895118-B2 | Negative dispersion retardation plate and achromatic circular polarizer | CRYSOPTIX K.K. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8416376-B2 | Compensated in-plane switching mode liquid crystal display | CRYSOPTIX KK (JP) | 2013-04-09 | — | — | US | disclosed |
| US-8416376-B2 | Compensated in-plane switching mode liquid crystal display | CRYSOPTIX KK (JP) | 2013-04-09 | — | — | US | disclosed |
| US-20120113380-A1 | NEGATIVE DISPERSION RETARDATION PLATE AND ACHROMATIC CIRCULAR POLARIZER | CRYSOPTIX KK (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120113380-A1 | NEGATIVE DISPERSION RETARDATION PLATE AND ACHROMATIC CIRCULAR POLARIZER | CRYSOPTIX KK (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8142863-B2 | Color liquid crystal display and compensation panel | Crysoptix, KK (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8142863-B2 | Color liquid crystal display and compensation panel | Crysoptix, KK (JP) | 2012-03-27 | — | — | US | disclosed |
| US-7889297-B2 | Liquid crystal display operating in a vertically aligned mode | Crysoptix, KK (JP) | 2011-02-15 | — | — | US | disclosed |
| US-7889297-B2 | Liquid crystal display operating in a vertically aligned mode | Crysoptix, KK (JP) | 2011-02-15 | — | — | US | disclosed |
| US-20100279122-A1 | Benzimidazole, Benzoxazole and Benzothiazole Derivatives, Optical Film Comprising them and Method of Producing thereof | CRYSOPTIX KK (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100279122-A1 | Benzimidazole, Benzoxazole and Benzothiazole Derivatives, Optical Film Comprising them and Method of Producing thereof | CRYSOPTIX KK (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100149471-A1 | Compensated In-Plane Switching Mode Liquid Crystal Display | CRYSOPTIX KK (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100149471-A1 | Compensated In-Plane Switching Mode Liquid Crystal Display | CRYSOPTIX KK (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100118241-A1 | Liquid Crystal Display Operating in a Vertically Aligned Mode | CRYSOPTIX KK (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20100118241-A1 | Liquid Crystal Display Operating in a Vertically Aligned Mode | CRYSOPTIX KK (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20090268136-A1 | Color Liquid Crystal Display and Compensation Panel | CRYSOPTIX KK (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090268136-A1 | Color Liquid Crystal Display and Compensation Panel | CRYSOPTIX KK (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279122-A1 | Benzimidazole, Benzoxazole and Benzothiazole Derivatives, Optical Film Comprising them and Method of Producing thereof | BMX, ABCG2, BRI3BP | HSD17B10 2693/4885TDP1 3607/4885HTT 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.